Leading the way to safer medication

Therapeutic Indications

Acemetacin is indicated for:

Osteoarthritis, rheumatoid arthritis, pain, inflammation

Irrespective of gender only Adults (18 - 65 years old)

Acemetacin is indicated for the treatment of rheumatoid arthritis, osteoarthritis, low back pain, and post-operative pain and inflammation.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 120-180 mg in 2-3 divided doses daily

Contraindications

Active ingredient Acemetacin is contraindicated in the following cases:

History of recurrent peptic ulcer/haemorrhage

No gender/age discrimination

Active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding).

Severe renal failure

No gender/age discrimination

Acemetacin is contraindicated in severe renal failure.

Severe heart failure

No gender/age discrimination

Acemetacin is contraindicated in severe heart failure.

Severe hepatic failure

No gender/age discrimination

Acemetacin is contraindicated in severe hepatic failure.

NSAIDS

No gender/age discrimination

Co-administration of acemetacin with other NSAIDS is contraindicated.

Breastfeeding

No gender/age discrimination

In limited studies so far available, NSAIDs can appear in breast milk in very low concentrations. NSAIDs should, if possible, be avoided when breastfeeding.

Last trimester of pregnancy

No gender/age discrimination

Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and post-implantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period. During the first and second trimester of pregnancy, acemetacin should not be given unless clearly necessary. If acemetacin is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.

During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:

  • cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension);
  • renal dysfunction, which may progress to renal failure with oligo-hydroamniosis;

The mother and the neonate, at the end of pregnancy, to:

  • possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses.
  • inhibition of uterine contractions resulting in delayed or prolonged labour.

Consequently, acemetacin is contraindicated during the third trimester of pregnancy.

Mifepristone

No gender/age discrimination

NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs can reduce the effect of mifepristone.

Nasal polyps associated with angioneurotic oedema

No gender/age discrimination

Acemetacin is contraindicated in nasal polyps associated with angioneurotic oedema.